Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-Mica/B Antibody, at ASCO 2023

May 25, 2023

Cullinan Oncology, Inc. today announced the first monotherapy clinical data from its Phase 1 study of CLN-619 in patients with advanced solid tumors. Findings from the clinical trial will be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting as a poster presentation during the “Developmental Therapeutics—Immunotherapy” session (poster # 2532) on June 3, 2023, from 8:00 AM-11:00 AM Central Time. CLN-619 is being studied in an ongoing Phase 1 clinical trial both as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.